IQVIA HOLDINGS INC.
No SEC Form 4 filings for $IQV in the last 30 days.
See all $IQV insider activity →IQVIA launched an AI platform, IQVIA Predictive Clinical Development, to speed up clinical trials. The company claims it can reduce study startup time by 33% and data cleaning time by 50%, with AI-prioritized sites showing higher patient enrollment rates and faster trial phases. The platform integrates data and technologies from multiple partners.
Azenta (AZTA) reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. Repligen (RGEN) reported $204.1M, up 11.9% YoY, with mixed guidance. Charles River Labs (CRL) reported $1.0B, down 2.7% YoY, but beat estimates. West Pharmaceutical (WST) reported $872.3M, up 13.8% YoY, beating estimates. Stocks reacted accordingly.
IQVIA Holdings (IQV) reported Q2 earnings that beat expectations, with adjusted earnings up 12.1% and revenue up 8.7% year over year. The company raised its 2026 guidance for revenue, adjusted EBITDA, and earnings, citing strong bookings and acquisitions. Management attributes the upgrade to broad-based demand and operational efficiency, including AI-driven initiatives like IQVIA.ai. The stock is projected to reach $20.4 billion in revenue and $2.0 billion in earnings by 2029, representing a 5%
Over the past 7 days, alphai's AI scored 3 news stories mentioning IQV (IQVIA HOLDINGS INC.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent IQV coverage spans technology, financial news and earnings.
Potential revenue uplift from AI services and stronger client retention.
Earnings beat likely supports short‑term upside.
Guidance upgrade suggests higher future cash flows, likely supporting a price rally.
Mild negative reaction as AI data‑services competition expands.
Potential upside as price targets increase.
alphai scores every news story that mentions IQV with an AI model for sentiment and relevance, and aggregates insider trades from IQVIA HOLDINGS INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
IQVIA launched an AI platform, IQVIA Predictive Clinical Development, to speed up clinical trials. The company claims it can reduce study startup time by 33% and data cleaning time by 50%, with AI-prioritized sites showing higher patient enrollment rates and faster trial phases. The platform integrates data and technologies from multiple partners.
2 min readAzenta (AZTA) reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. Repligen (RGEN) reported $204.1M, up 11.9% YoY, with mixed guidance. Charles River Labs (CRL) reported $1.0B, down 2.7% YoY, but beat estimates. West Pharmaceutical (WST) reported $872.3M, up 13.8% YoY, beating estimates. Stocks reacted accordingly.
3 min readIQVIA Holdings (IQV) reported Q2 earnings that beat expectations, with adjusted earnings up 12.1% and revenue up 8.7% year over year. The company raised its 2026 guidance for revenue, adjusted EBITDA, and earnings, citing strong bookings and acquisitions. Management attributes the upgrade to broad-based demand and operational efficiency, including AI-driven initiatives like IQVIA.ai. The stock is projected to reach $20.4 billion in revenue and $2.0 billion in earnings by 2029, representing a 5%
2 min readAnthropic launched Claude Science, a research workbench integrating existing AI models with 60+ scientific databases. The company's enterprise revenue is projected to reach $47B by late 2026. Claude is also being adapted for financial services, connecting with data providers and Microsoft apps. Anthropic emphasizes both model development and enterprise integration for competitive advantage.
3 min readWall Street analysts overwhelmingly rate IQVIA Holdings a 'Strong Buy,' with 16 of 20 recommending it. Baird raised its price target to $249, citing AI adoption in clinical trials. The mean target is $268.31, a 4.8% premium to current levels.
1 min readIQVIA Inc. said it raised full-year 2026 revenue guidance to US$17.28–US$17.48 billion, with Q3 outlook of US$4.32–US$4.39 billion, alongside reporting Q2 results and buyback activity. IQVIA also announced a collaboration with Medera Inc. on cardiac gene therapies and human-based drug discovery, linking IQVIA trial and platform capabilities to Medera programs.
6 min readIQVIA Holdings said it will expand its partnership with Medera to support cardiac gene therapies and human-based drug discovery using IQVIA’s clinical and regulatory infrastructure. The article also cites raised 2026 revenue guidance, Q2 results, and ongoing share repurchases. It discusses valuation, including a $232 fair value versus a $232.43 close and a DCF implying ~36% below cash-flow value.
6 min readSTAUB W RICHARD (See Remarks) sold 5,500 shares of IQVIA HOLDINGS INC. (IQV) at $232.68 ($1.28M total) on 2026-08-03.
1 min readPatel Bhavik (See Remarks) sold 1,855 shares of IQVIA HOLDINGS INC. (IQV) at $235.27 ($0.44M total) on 2026-07-31.
1 min readIQVIA (NYSE:IQV) and Medera will collaborate to advance Medera’s Sardocor cardiac AAV-based gene therapy programs and Novoheart mini-Heart human tissue platform. IQVIA will support patient recruitment, data quality and regulatory filings, including expedited FDA designations. Novoheart’s platform has supported IND and Fast Track designations and is expanding under FDA Modernization Act 2.0.
3 min read
